Effects of dyslipidemia on E antigen seroconversion of patients with chronic hepatitis B treated by nucleoside (acid) analogs

BACKGROUND: The prevalence of dyslipidemia in China is increasing annually. Current studies suggest that dyslipidemia affects the antiviral efficacy of hepatitis C virus (HCV) therapies, while recent studies suggest that serum lipids influence the response rates of chronic hepatitis B (CHB) patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Ziqiang, Zheng, Juzeng, Zheng, Liang, Zheng, Endian, Zou, Zhuolin, Sheng, Xiong, Wu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557562/
https://www.ncbi.nlm.nih.gov/pubmed/34717643
http://dx.doi.org/10.1186/s12944-021-01582-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557562/
https://www.ncbi.nlm.nih.gov/pubmed/34717643
http://dx.doi.org/10.1186/s12944-021-01582-x

Ejemplares similares